The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 06, 2023

Filed:

Apr. 13, 2017
Applicant:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Inventors:

Kameswara Rao Kuchimanchi, Lexington, MA (US);

Alexandra Loew-Baselli, Vienna, AT;

Gerald Spotts, Encino, CA (US);

Myungshin Oh, Los Angeles, CA (US);

Michael Don Hale, Winchester, MA (US);

Martin Wolfsegger, Vienna, AT;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16H 20/17 (2018.01); G16H 50/70 (2018.01); G16H 50/20 (2018.01); G16C 20/30 (2019.01); G16H 50/50 (2018.01); G16C 20/50 (2019.01); G16C 20/70 (2019.01); A61P 7/04 (2006.01); A61K 49/00 (2006.01); G06N 7/01 (2023.01);
U.S. Cl.
CPC ...
G16H 20/17 (2018.01); G16C 20/30 (2019.02); G16H 50/20 (2018.01); G16H 50/50 (2018.01); G16H 50/70 (2018.01); A61K 49/0004 (2013.01); A61P 7/04 (2018.01); G06N 7/01 (2023.01); G16C 20/50 (2019.02); G16C 20/70 (2019.02);
Abstract

Systems and methods for providing a clotting factor VIII (CFVIII) dosing regimen include collecting two blood samples from a patient after an infusion of CFVIII and determining a CFVIII clearance based on the two blood samples, and determining if a patient has a half-life greater than a predetermined threshold. A pharmacokinetic (PK) profile of the patient is determined using a Bayesian model of pharmacokinetic profiles of sampled patients having similar body weight or age of the patient. A first weight is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is greater than the predetermined threshold, and a second weight, less than the first weight, is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is less than the predetermined threshold. A dosing regimen is determined for the patient based on the PK profile.


Find Patent Forward Citations

Loading…